Screening identifies actionable findings across multiple health domains
Our active contracts use cardiovascular and, in selected programs, multi-organ ultrasound screening. Because the scope of each contract differs, condition-specific rates use the records in which that screening component was documented.
Multi-organ rates use 723 screening records from contracts that included these screening elements.
Valvular Assessment
In the 308-record cohort with available valvular findings, 37 participants (12.0%) had at least one documented valvular abnormality. The counts below describe individual valve findings and may overlap within participants. These results are not pooled across all five screening contracts.
Findings that can support earlier follow-up
A screening result is not a final diagnosis. Its value is in identifying findings that may benefit from physician interpretation, primary-care follow-up, risk-factor management, surveillance, or additional diagnostic evaluation.
Abnormal EKG results
Among 590 records with documented EKG data, 16.8% were abnormal.
Thyroid FNA recommendations
Fine-needle aspiration was recommended in 4.1% of multi-organ screening records. Recommendation does not mean cancer was diagnosed.
Fatty liver findings
Detected in 24.2% of multi-organ screening records, supporting opportunities for metabolic-health education and follow-up.
Abdominal aortic aneurysm findings
Low-frequency findings can still carry high clinical importance and demonstrate the value of targeted vascular screening.
Thyroid abnormalities
Detected in 19.1% of screening records from contracts that included thyroid evaluation.
Thyroid follow-up ultrasounds
Recommended to support surveillance or further evaluation when clinically appropriate.
Valvular abnormalities
At least one valve finding was documented in 12.0% of the 308 participants with available valvular assessment data.
These figures are intentionally de-identified and do not include municipality, department, station, precinct, or participant-level information. The valvular assessment row reflects only the cohort with available valve data.
| Metric | Findings | Eligible records | Rate |
|---|---|---|---|
| Overall abnormal classification | 592 | 1,030 | 57.5% |
| Carotid stenosis | 71 | 860 | 8.3% |
| Abdominal aortic aneurysm | 5 | 1,030 | 0.49% |
| Reduced ejection fraction (<50%) | 83 | 942 | 8.8% |
| Hyperdynamic ejection fraction (>75%) | 60 | 942 | 6.4% |
| Abnormal EKG | 99 | 590 | 16.8% |
| At least one valvular abnormality (documented cohort only) | 37 | 308 | 12.0% |
| Thyroid abnormality | 138 | 723 | 19.1% |
| Thyroid follow-up ultrasound recommended | 84 | 723 | 11.6% |
| Thyroid FNA recommended | 30 | 723 | 4.1% |
| Fatty liver | 175 | 723 | 24.2% |
| Hepatomegaly | 126 | 723 | 17.4% |
What these screening programs are designed to do
Our screening contracts are intended to create an accessible pathway from screening to physician interpretation and appropriate follow-up. Aggregate data can also help municipal partners identify recurring wellness themes such as blood-pressure control, cardiovascular risk, metabolic health, and the importance of routine primary care.